Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process.

In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it works on transforming this landscape by launching the world’s first GMP validated AVA detection test based on Oxford Nanopore sequencing. This first in class solution consolidates multiple assays into a single, comprehensive test, enabling broader viral detection, faster time to result, and more confident decision making in regulated QC environments.

The speaker is Hans-Peter Fasching, Deputy Head of the Molecular Biology Department, ViruSure, with an introduction by Carrie Maynard, Associate Director, Biopharma Segment, Oxford Nanopore Technologies.

You will learn: 

  • How NGS sequencing can be used to improve testing timelines in an AVA test 
  • How a single, comprehensive test can enable broader viral detection 
  • The benefits of sequencing to support operational efficiency, stronger supply chain resilience, and more ethical testing practices

Watch now to find out more.